Digitoxin is a cardiac glycoside that inhibits the Na/K-ATPase pump, increasing intracellular calcium and thereby enhancing myocardial contractility, used for heart failure and atrial arrhythmias with a very narrow therapeutic index. Simson Pharma's Digitoxin reference standard and impurities support the rigorous potency control this narrow-margin cardiac glycoside demands.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Digitoxin Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.